title: Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
authors.affiliation: Division of Hematology/Oncology, Northwestern University, Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA. l-gordon@northwestern.edu
authors.forename: Leo I
authors.initials: LI
authors.lastname: Gordon
authors.forename: Thomas
authors.initials: T
authors.lastname: Witzig
authors.forename: Arturo
authors.initials: A
authors.lastname: Molina
authors.forename: Myron
authors.initials: M
authors.lastname: Czuczman
authors.forename: Christos
authors.initials: C
authors.lastname: Emmanouilides
authors.forename: Robin
authors.initials: R
authors.lastname: Joyce
authors.forename: Katie
authors.initials: K
authors.lastname: Vo
authors.forename: Charles
authors.initials: C
authors.lastname: Theuer
authors.forename: Brad
authors.initials: B
authors.lastname: Pohlman
authors.forename: Nancy
authors.initials: N
authors.lastname: Bartlett
authors.forename: Greg
authors.initials: G
authors.lastname: Wiseman
authors.forename: Mohamed
authors.initials: M
authors.lastname: Darif
authors.forename: Christine
authors.initials: C
authors.lastname: White
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002461:Cell Line, Transformed; D002986:Clinical Trials as Topic; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008224:Lymphoma, Follicular / Q000473:pathology; D016499:Radioimmunotherapy / Q000379:methods*; D012074:Remission Induction; D000069283:Rituximab; D013997:Time Factors; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D015021:Yttrium Radioisotopes; D000069283:Rituximab; C422802:ibritumomab tiuxetan